Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
← catalyst calendarNCT06429761 · readout in 73 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100estimated
Sites
6
Country
India
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-02 | actual | When the study began enrolling |
| Primary completion | 2026-10-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- BREAST CANCER
Intervention
- Drug: Trastuzumab deruxtecan
Primary outcome
what the primary-completion date above is the date OFTo assess the safety of trastuzumab deruxtecan in adult Indian patients
measured 6 Months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed